Type your tag names separated by a space and hit enter

buserelin

General

Canada-Approved Medicine

This monograph describes a medication approved for use in Canada by the Therapeutic Products Directorate, a division of Health Canada’s Health Products and Food Branch. The medication is not approved by the United States Food and Drug Administration; however, a similar formulation carrying a different generic or brand name might be available in the US.

Pronunciation:
bue-se-rel-in

Trade Name(s)

  • Suprefact Canadian Tradename

Ther. Class.
antineoplastics
hormones

Pharm. Class.
luteinizing hormone-releasing hormone (LHRH) analogues

Indications

  • Subcutaneous injection– Initial and maintenance palliative treatment of advanced hormone-dependent prostate cancer (usually given with an anti-androgen).
  • Nasal solution– Maintenance palliative treatment of advanced hormone-dependent prostate cancer (usually given with an anti-androgen).
  • Nasal solution– Non-surgical treatment of endometriosis (course of treatment 6–9 mo).

Action

Acts as a synthetic analog of endogenous gonadotropin-releasing hormone (GnRH/LHRH). Chronic use results in inhibited secretion of gonadotropin release and gonadal steroid production. The overall effect is due to down-regulation of pituitary LHRH receptors. In males, testosterone synthesis and release is decreased. In females, secretion of estrogen in decreased.

Therapeutic Effect(s):

  • Decreased spread of advanced prostate cancer.
  • Decreased sequelae of endometriosis (pain, dysmenorrhea).

Pharmacokinetics

Absorption: Subcut– 70%; intranasal– 1–3%; implant– drug is slowly absorbed over 2–3 mo.

Distribution: Accumulates in liver, kidneys and anterior pituitary lobe; enters breast milk in small amounts.

Metabolism and Excretion: Metabolized in liver, kidneys and by enzymes on membranes in the pituitary gland.

Half-life: Subcut– 80 min; intranasal– 1–2 hr; implant– 20–30 days.

TIME/ACTION PROFILE

ROUTEONSETPEAKDURATION
prostate cancer †7 days4 mosuntil discontinuation
endometriosis ‡(intranasal)unknownunknownduration of treatment
†↓ in testosterone levels.‡Symptom improvement.

Contraindication/Precautions

Contraindicated in:

  • Hypersensitivity;
  • Non-hormonal-dependent prostate cancer or previous orchiectomy;
  • Females with undiagnosed vaginal bleeding;
  • OB: Pregnancy (avoid use);
  • Lactation:Avoid breast feeding (small amounts enter breast milk; injection contains benzyl alcohol).

Use Cautiously in:

  • Prostate cancer with urinary tract obstruction or spinal lesions;
  • Pedi: Safety and effectiveness not established (injection contains benzyl alcohol).

Adverse Reactions/Side Effects

CNS: depression, dizziness

CV: hypertension

Endo: glucose intolerance

Hemat: anemia

Local: injection site reactions

MS: osteoporosis (long-term use

Misc: transient exacerbation of metastatic prostate cancer or endometriosis

Prostate cancer

CNS: headache (nasal solution)

EENT: nasal irritation (nasal spray)

GU: ↓ libido, impotence

Derm: hot flushes

Endo: gynecomastia, testosterone flair

MS: bone pain

Endometriosis

CNS: headache, weakness, insomnia

CV: edema

GI: constipation, gastrointestinal disorders, nausea

GU: ↓ libido, vaginal dryness, menorrhagia

Derm: hot flushes, acne

Endo: supression of ovulation

MS: back pain

* CAPITALS indicate life-threatening.
Underline indicate most frequent.

Interactions

Drug-Drug

Risk of serious arrhythmias may be↑ by concurrent amiodarone, disopyramide, dofetilide, flecainide ibutilide, propafenone quinidine, sotalol, antipsychotics (including chlorpromazine) antidepressants (including amitrypline and nortriptyline ), opioids (including methadone ), macrolide anti-infectives (including azithromycin, erythromycin and clarithromycin ), fluoroquinolones (including moxifloxacin ), azole antifungals, 5-HT3 antagonists (including ondansetron ), beta-2 receptor agonists (including salbutamol ), pentamidine, and quinine.

Route/Dosage

Prostate cancer

SC: (Adults) Initial treatment– 500 mcg every 8 hr for 7 days, Maintenance treatment– 200 mcg daily.

Intranasal: (Adults) Maintenance treatment– 400 mcg (200 mcg in each nostril) 3 times daily.

Subcut implant: (Adults) 6.3 mg every 2 mo or 9.45 mg every 3 mo.

Endometriosis

Intranasal: (Adults) 400 mcg (200 mcg in each nostril) 3 times daily. Treatment is usually continued for 6 mo; not to exceed 9 mo.

Availability

Solution for subcutaneous injection (contains benzyl alcohol): 1000 mcg/mL

Intranasal Solution : 1000 mcg/mL (delivers 100 mcg per actuation)

Subcutaneous implant (depot): 6.3 mg (2–mo implant), 9.45 mg (3–mo implant)

Assessment

  • Cancer: Monitor patients with vertebral metastases for increased back pain and decreased sensory/motor function.
  • Monitor intake and output ratios and assess for bladder distention in patients with urinary tract obstruction during initiation of therapy.
  • Endometriosis: Assess for signs and symptoms of endometriosis before and periodically during therapy. Amenorrhea usually occurs within 8 wk of initial administration and menses usually resume 8 wk after completion.

Lab Test Considerations: Monitor serum testosterone levels every 3 mo during treatment with male patients. When treatment begins, testosterone levels can temporarily markedly ↑ and patients may need another medication to ↓ levels.

  • Monitor blood glucose in patients with diabetes frequently; may affect blood glucose levels.
  • Verify negative pregnancy test before starting therapy for women.

Potential Diagnoses

  • Sexual dysfunction
  • Disturbed body image

Implementation

Prostate Cancer

  • SC: Only use syringes that come with kit for accurate dose. Inject into fatty tissue of abdomen, arm, or leg 3 times/day for 7 days; then daily during maintenance.
  • Intranasal: When used as maintenance, begin nasal spray in each nostril 3 times daily. If patient also receives decongestant nasal spray, wait 30 minutes to give buserelin spray before or after the decongestant.
  • Implant: Implant is inserted in subcut tissue of upper abdominal wall every 28 days. Local anesthesia may be used before injection.
    • If the implant needs to be removed for any reason, it can be located by ultrasound.

Endometriosis

  • Intranasal: One spray in each nostril 3 times daily for 6–9 mo.

Patient/Family Teaching

  • Inform male patients that they may experience breast swelling and tenderness, decreased libido, hot flashes and sweats, impotence and weight gain. Notify health care professional if these symptoms occur.
  • Inform female patients that they may experience decreased libido, constipation, painful sexual intercourse, menopausal symptoms, changes in hair growth. Notify health care professional if these symptoms occur.
  • Caution both male and female patients to use contraception while taking this drug. Advise female patient to inform health care professional if pregnancy is suspected. Buserelin can be harmful to a fetus.
  • SC: Instruct patient in proper technique for self-injection, care and disposal of equipment. Use only syringes included in kit. Instruct patients that syringes may only be used once, and then discarded.
  • Intranasal: Instruct patient on proper nasal spray technique. Prime pump before use.
  • Advise patients that the nasal spray can cause nose bleeds, and may change smell and taste senses.

Evaluation/Desired Outcomes

  • Decrease in the spread of prostate cancer.
  • Decrease in lesions and pain in endometriosis.
buserelin is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Nursing Central is the award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Learn more.

Citation

Quiring, Courtney, et al. "Buserelin." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Nursing Central, nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109846/all/buserelin.
Quiring C, Sanoski CA, Vallerand AH. Buserelin. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109846/all/buserelin. Accessed April 23, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Buserelin. In Davis's Drug Guide. Available from https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109846/all/buserelin
Quiring C, Sanoski CA, Vallerand AH. Buserelin [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 April 23]. Available from: https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109846/all/buserelin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - buserelin ID - 109846 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109846/all/buserelin PB - F.A. Davis Company ET - 16 DB - Nursing Central DP - Unbound Medicine ER -